Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc anal...

Full description

Bibliographic Details
Main Authors: Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, Branimir Anić, Matija Tomšič, Vadim Mazurov, Marija Maksimovic, Orsolya Nagy, Jerzy Świerkot, Tzvetanka Petranova, Tiina Veldi, Asta Baranauskaitė, Catalin Codreanu, Daina Andersone, Roy Fleischmann
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-10-01
Series:Drugs in Context
Subjects:
eastern europe
rheumatoid arthritis
safety
treatment efficacy
upadacitinib
Online Access:https://www.drugsincontext.com/upadacitinib-versus-placebo-or-adalimumab-with-background-methotrexate-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-methotrexate

Internet

https://www.drugsincontext.com/upadacitinib-versus-placebo-or-adalimumab-with-background-methotrexate-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-methotrexate

Similar Items